Digital biomarkers in urology

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034652

Enrollment

300

Registered

2024-07-18

Start date

2024-08-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Patients who are 18 years or older with histologically confirmed prostate cancer, renal cell carcinoma, or urothelial carcinoma, for whom systemic therapy is planned. On Day 1 of the study, p

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Urooncological disease Planned systemic therapy Consent

Exclusion criteria

Exclusion criteria: Patients that do not consent No urooncological disease

Design outcomes

Primary

Measure	Time frame
Opinion and frequency of use of the wearable. The endpoint will be assessed at baseline as well as after 3 and 6 months.	—

Secondary

Measure	Time frame
Progression free survival Toxicity Quality of Life	—

Countries

Germany

Contacts

Public ContactSeverin Rodler

Klinikum der Universität München

severin.rodler@med.uni-muenchen.de089 4400 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026